ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 201

High Rate of Autoimmune Manifestations During Idiopathic CD4 Lymphocytopenia

Alexis Régent1, Brigitte Autran2, Guislaine Carcelain2, Benjamin Terrier3, Alain Krivitzky4, Eric Oksenhendler5, Nathalie Costedoat-Chalumeau6, Pascale Hubert2, Olivier Lortholary7, Nicolas Dupin8, Patrice Debré2, Loic Guillevin9 and Luc Mouthon1, 1Internal Medicine, Hopital Cochin, Paris, France, 2INSERM, UMR945, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire d'Immunologie Cellulaire Et Tissulaire, Paris, France, 3National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 4Département de médecine interne, Hôpital Avicenne, AP-HP, Bobigny, France, 5Département d'Immunologie Clinique, Hôpital Saint-Louis, AP-HP, Paris, France, 6Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 7Service de maladies infectieuses, Hôpital Necker-Enfants malades, AP-HP, Paris, France, 8Service de Dermatologie, Hôpital Cochin, AP-HP, Paris, France, 9Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Auto-immunity, B cells, infection and morbidity and mortality, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes

Session Type: Abstract Submissions (ACR)

Background/Purpose: When first described by the Center for Disease Control, idiopathic CD4 lymphocytopenia (ICL) was characterized by opportunistic infections in patients with a CD4 count≤300/mm3 or ≤20% lymphocytes. It is now well established that auto-immune manifestations occur during primary or secondary immunodeficiencies.

Methods: We prospectively included 36 patients (21 females) with ICL between January 1991 and June 2011. T lymphocyte phenotyping and lymphocyte proliferation assay were realized at diagnosis. Infectious, autoimmune manifestations and malignancies during a mean follow-up of 7.6±6.7 years were recorded and correlated with data at inclusion.

Results:

Twenty four patients showed infections (11 with human papillomavirus infection), 11 autoimmune symptoms, 5 malignancies and 7 mild or no symptoms. Autoimmune and/or inflammatory manifestations include immune thrombocytopenic purpura (n=5), autoimmune hemolytic anemia (n=3), central nervous system vasculitis (n=1), Goodpasture syndrome (n=1), grade II duodenal villous atrophy (n=1), Crohn disease (n=1), antiphospholipid syndrome (n=1) and Hashimoto’s thyroiditis (n=1). At the time of diagnosis, mean CD4+, CD8+, CD19+ and natural killer (NK) cell counts were 126/mm3 (range 4–294), 238/mm3 (1–1293), 107/mm3 (3–547) and 115/mm3 (5–416), respectively. Most patients exhibited deficiency in CD8+, CD19+, and/or NK cells. Patients with infections had a significantly lower NK cell count (p=0.03) and those with autoimmune manifestations higher CD45RO+CD8+ count (p=0.02). T-cell proliferation induced by mitogens and antigens revealed great discrepancies. Six patients died (16.6%) during follow-up. CD4+ T-cell count < 150/mm3 and NK cell count <100/mm3 were predictors of death.

Conclusion:

30.5 % patients with ICL show auto-immune manifestations during clinical course. These patients had higher CD45RO+CD8+ count at diagnosis. In addition to CD4 lymphocytopenia, patients often have CD8, CD19 and NK cell defects. Mortality is related to an initial CD4+ count≤ 150/mm3 and NK cells≤100/mm3.


Disclosure:

A. Régent,
None;

B. Autran,
None;

G. Carcelain,
None;

B. Terrier,
None;

A. Krivitzky,
None;

E. Oksenhendler,
None;

N. Costedoat-Chalumeau,
None;

P. Hubert,
None;

O. Lortholary,
None;

N. Dupin,
None;

P. Debré,
None;

L. Guillevin,
None;

L. Mouthon,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-rate-of-autoimmune-manifestations-during-idiopathic-cd4-lymphocytopenia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology